Drugs /

tesevatinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4). This may result in the inhibition of tumor growth and angiogenesis, and tumor regression.

Clinical Trials

View Clinical Trials for tesevatinib

Tesevatinib has been investigated in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials investigating tesevatinib, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (0 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for tesevatinib clinical trials.

Breast carcinoma and non-small cell lung carcinoma are the most common diseases being investigated in tesevatinib clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Tesevatinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tesevatinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
4-quinazolinamine, n-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-(((3aalpha,5beta,6aalpha)-octahydro-2-methylcyclopenta(c)pyrrol-5-yl)methoxy)-, tesevatinib, kd 019, receptor tyrosine kinase inhibitor xl647, exel-7647, exel 7647, xl647
Drug Categories [2]:
Tyrosine kinase inhibitors
Drug Target(s) [2]:
EGFR, EPHB4, ERBB2, FLT4, KDR
NCIT ID [1]:
C62496

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.